论文部分内容阅读
本实验用双抗体夹心ELISA法检测29例肝癌患者血清SIL—2R，并与30例健康人对照。结果显示：①肝癌病人血清SIL—2R464．75士45．9lu／ml，肝癌病人血清SIL—2R水平明显高于健康对照组（P＜0．05）。②对经手术、化疗、免疫等综合治疗有反应者Sll一2R降低，病情恶化SIL—2R升高。结论：肝癌病人机体免疫功能低下，出现免疫抑制物SIL一2R水平增高的现象，提示检测SIL—2R对临床治疗具有重要意义。
In this experiment, serum SIL-2R was detected in 29 patients with liver cancer by double antibody sandwich ELISA and compared with 30 healthy people. The results showed that: 1 serum SIL-2R464.75 ± 45.9lu/ml liver cancer patients, serum SIL-2R levels in liver cancer patients was significantly higher than the healthy control group (P <0.05). 2 Sll-2R decreased in response to comprehensive treatment such as surgery, chemotherapy, and immunization, and the condition deteriorated with elevated SIL-2R. Conclusion: The immune function of liver cancer patients is low, and there is an increase in the level of SIL-2R in the immunosuppressive agent, suggesting that the detection of SIL-2R is of great significance for clinical treatment.